Abstract Library

#4028 Clinical application of digital pathology: Proposal of a new G0 category useful in small intestinal NET (SI-NET)

Introduction: SI-NET display low proliferation rate despite a high frequency of metastases. Ki67 index is frequently reported as “

Conference:

Presenting Author: Couvelard A

Authors: Guedj N, Cléry G, Chassac A, Hentic O, Colnot N,

Keywords: Small Intestinal NET-, grade, survival, prognosis, G1,

#4027 Prognostic impact of molecular signatures in pancreatic metastatic neuroendocrine tumors (PRODETEN)

Introduction: Pancreatic neuroendocrine neoplasms (PNENs) are an heterogenous group of tumors. This heterogeneity is not explained by the main known prognostic factors (extension, evolution slope and Ki67 index). New molecular biomarkers (ARX, ATRX, DAXX, menin, PDX1) seem promising in non-metastatic PNENs.

Conference:

Presenting Author: de Mestier L

Authors: Pokossy Epee J, Cros J, Cadiot G, Do Cao C, Hautefeuille V,

Keywords: pancreas, neuroendocrine, prognostic, ATRX, daxx, arx, pdx1, Super Learner, menin, biomarker,

#3523 NICENEC phase 2 trial of nivolumab and platinum-doublet chemotherapy in untreated advanced G3 Neuroendocrine Neoplasms (NENs) of gastroenteropancreatic (GEP) or unknown (UK) origin: Efficacy by differentiation, KI67 index and primary tumor site

Introduction: G3 NENs are aggressive tumors with limited treatment options. Prognosis is rather poor even with best available platinum-based CT (OS of 11m).

Conference:

Presenting Author:

Authors: Riesco-Martinez M, Capdevila J, Alonso V, Jimenez-Fonseca P, Teulé A,

Keywords: Grade 3 Neuroendocrine Neoplasm, nivolumab, gastroenteropancreatic,

#3283 Tumor growth rate in well-differentiated G1-3 gastroenteropancreatic neuroendocrine tumors (GEP-NETs): Implications for clinical trials

Introduction: Drug development in G1-3 GEP-NETs is hampered by heterogeneous tumor biology and the cytostatic nature of most active agents. Optimal care of G3NETs is ill-defined, as recent phase 3 studies have not accounted for this group. Tumor growth rate (TGR) allows dynamic evaluation of growth and has prognostic value in G1-2; little is known about TGR in G3.

Conference: 18th Annual ENETS Concerence (2021)

Presenting Author:

Authors: Wang S, Whitman J, Paciorek A, Le B, Zhang L,

Keywords: GEP-NET, tumor growth rate, Ki67,

#3036 Can Ki-67 with 5.5% Be Better in Predicting Prognosis for Well Differentiated Pancreatic Neuroendocrine Tumors?

Introduction: Pancreatic neuroendocrine tumors (NETs) are rare malignancies, Ki-67 is a cell proliferation marker that has been shown to have some utility in predicting prognosis of neuroendocrine tumors. However, the ideal grading method for G1/G2 remains controversial.

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author: Tan H

Authors: Yuan B, Chen Y, Zhang P, Wang X, Tan H,

Keywords: Pancreatic net, G1, G2, Ki-67, overall survival time,